CHARLES RIVER LABORATORIES (CRL) Stock Analyst Ratings
NYSE:CRL - New York Stock Exchange, Inc. - US1598641074 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 66% to CRL. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 191.96. This target is 15.74% above the current price.
CRL was analyzed by 25 analysts. The buy percentage consensus is at 66. So analysts seem to be have mildly positive about CRL.
In the previous month the buy percentage consensus was at a similar level.
CRL was analyzed by 25 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-02-20 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-02-20 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-02-20 | Baird | Maintains | Neutral -> Neutral |
| 2025-02-18 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-02-05 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-02-03 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-01-23 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-01-22 | William Blair | Downgrade | Outperform -> Market Perform |
| 2025-01-17 | UBS | Downgrade | Buy -> Neutral |
| 2025-01-14 | William Blair | Reiterate | Outperform -> Outperform |
| 2024-12-13 | B of A Securities | Maintains | Neutral -> Neutral |
| 2024-11-11 | TD Cowen | Maintains | Hold -> Hold |
| 2024-11-07 | UBS | Maintains | Buy -> Buy |
| 2024-11-07 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2024-10-23 | CLSA | Initiate | Underperform |
| 2024-10-14 | Redburn Atlantic | Initiate | Sell |
| 2024-10-07 | Evercore ISI Group | Downgrade | Outperform -> In-Line |
| 2024-10-02 | B of A Securities | Downgrade | Buy -> Neutral |
| 2024-10-01 | Citigroup | Downgrade | Neutral -> Sell |
| 2024-09-20 | Baird | Maintains | Neutral -> Neutral |
| 2024-08-12 | TD Cowen | Maintains | Hold -> Hold |
| 2024-08-08 | UBS | Maintains | Buy -> Buy |
| 2024-08-08 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2024-08-08 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2024-08-08 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2024-08-08 | Baird | Downgrade | Outperform -> Neutral |
| 2024-08-08 | Goldman Sachs | Maintains | Buy -> Buy |
| 2024-07-10 | Baird | Maintains | Outperform -> Outperform |
| 2024-06-28 | Argus Research | Downgrade | Buy -> Hold |
| 2024-06-28 | Barclays | Initiate | Equal-Weight |